D. E. Shaw & Co., Inc. Lineage Cell Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 25,584 shares of LCTX stock, worth $14,327. This represents 0.0% of its overall portfolio holdings.

Number of Shares

25,584

Holding current value

$14,327

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.8 - $1.12 $96,485 - $135,079	-120,607 Reduced 82.5%	25,584 $23,000
Q2 2024 Aug 14, 2024	SELL	$0.89 - $1.47 $35,988 - $59,440	-40,436 Reduced 21.67%	146,191 $146,000
Q1 2024 May 15, 2024	BUY	$0.86 - $1.48 $160,499 - $276,207	186,627 New	186,627 $276,000
Q3 2023 Nov 14, 2023	SELL	$1.16 - $1.53 $82,894 - $109,335	-71,461 Reduced 58.25%	51,220 $60,000
Q2 2023 Aug 14, 2023	BUY	$1.26 - $1.53 $154,578 - $187,701	122,681 New	122,681 $172,000
Q2 2022 Aug 15, 2022	SELL	$1.12 - $1.61 $49,935 - $71,781	-44,585 Reduced 80.38%	10,886 $17,000
Q1 2022 May 16, 2022	SELL	$1.21 - $2.48 $241,208 - $494,378	-199,346 Reduced 78.23%	55,471 $85,000
Q4 2021 Feb 14, 2022	BUY	$1.84 - $2.68 $123,889 - $180,447	67,331 Added 35.91%	254,817 $624,000
Q3 2021 Nov 15, 2021	BUY	$2.26 - $2.86 $366,723 - $464,083	162,267 Added 643.43%	187,486 $472,000
Q2 2021 Aug 16, 2021	BUY	$2.17 - $3.0 $54,725 - $75,657	25,219 New	25,219 $72,000
Q4 2019 Feb 14, 2020	SELL	$0.54 - $1.01 $5,591 - $10,457	-10,354 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$0.85 - $1.24 $8,800 - $12,838	10,354 New	10,354 $10,000

Others Institutions Holding LCTX

# of Institutions

120

Shares Held

94.2M

Call Options Held

63.8K

Put Options Held

View Full List

About Lineage Cell Therapeutics, Inc.

Ticker LCTX
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 169,755,008
Market Cap $95.1M
Description
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...

More about LCTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account